Articles | Volume 7, issue 4
https://doi.org/10.5194/jbji-7-169-2022
https://doi.org/10.5194/jbji-7-169-2022
Original full-length article
 | 
27 Jul 2022
Original full-length article |  | 27 Jul 2022

Locally delivered antistaphylococcal lysin exebacase or CF-296 is active in methicillin-resistant Staphylococcus aureus implant-associated osteomyelitis

Melissa Karau, Suzannah Schmidt-Malan, Jay Mandrekar, Dario Lehoux, Raymond Schuch, Cara Cassino, and Robin Patel

Viewed

Total article views: 1,224 (including HTML, PDF, and XML)
HTML PDF XML Total BibTeX EndNote
966 213 45 1,224 40 43
  • HTML: 966
  • PDF: 213
  • XML: 45
  • Total: 1,224
  • BibTeX: 40
  • EndNote: 43
Views and downloads (calculated since 27 Jul 2022)
Cumulative views and downloads (calculated since 27 Jul 2022)

Viewed (geographical distribution)

Total article views: 1,169 (including HTML, PDF, and XML) Thereof 1,169 with geography defined and 0 with unknown origin.
Country # Views %
  • 1
1
 
 
 
 

Cited

Latest update: 12 Jul 2024
Download
Short summary
Orthopedic infections are complex, often requiring surgical intervention and prolonged antibiotic therapy, especially in the presence of a foreign body. In a rabbit model of implant-associated methicillin-resistant Staphylococcus aureus osteomyelitis, the lysins exebacase and CF-296 delivered locally with and without systemic daptomycin resulted in lower bacterial counts than those of control animals, showing a promising complement to conventional antibiotics in implant-associated infections.